Tuesday, September 24, 2024 - Day One of Main Conference - EST/EDT (Eastern Daylight, GMT-4)
Tuesday, September 24, 2024 - Day One of Main Conference - EST/EDT (Eastern Daylight, GMT-4)
- Ron Weiss - Professor of Biological Engineering, MIT Synthetic Biology Lab
- Thomas Kelly - Director, Cell Engineering & Analytical Sciences, Johnson & Johnson Innovative Medicine
Transposase/Transposon platforms have become increasingly common for the development of robust high-expressing CHO cell lines for protein therapeutic manufacturing. Notably, these techniques use a single transposase/transposon pair to enable such outcomes. ATUM, as part of the Leap In Transposase platform, has developed a number of mutually orthogonal transposase/transposon pairs that can be used to serially engineer CHO, and other, cell lines in a robust manner. Indeed, this engineering can be used to not only increase the expression of transgenes, as is the case for a mAb therapeutics, but also knock-down the expression of endogenous genes to affect cellular physiology and/or product quality attributes … or both. This talk will provide examples of such engineering including a case study wherein three orthogonal Leap In Transposase/Transposon systems were implemented for the creation of a mAb expressing cell line with specific product quality attributes.
- Oren Beske, Ph.D. - Amalgamator of Business and Biology, ATUM
In the biopharma industry, various techniques are utilized to enhance yield and quality of the target protein produced by stable cell pools and accelerate overall CLD timeline. In this presentation, we will show a case study of a method for minipool productivity enrichment via co-expression of the target protein with a fluorescent biosensor protein using an IRES, combined with state-of-the-art automation tools to allow productivity enhancement and reduce timeline for overall cell line development efforts.
- Jishna Ganguly - Expert Scientist, GSK
Cell Line Development plays a crucial role in establishing Master Cell Banks for clinical and commercial biomanufacturing. This involves creating subclones and undergoing multiple stages of rigorous assessment, leading to the selection of a final clone used for the project's entire duration. Decision-making in this process hinges on extensive datasets obtained from advanced analytical methods. The introduction of high-throughput platforms like the Berkeley Light Beacon and automated micro-bioreactor systems has resulted in generating vast datasets, which often consist of thousands of data points in each experiment. Moreover, the need to integrate process and performance data from various scales, including deep-well plates, shake flasks, and bioreactor processes, is essential for a thorough analysis. Collectively, these factors pose significant challenges in data processing and analysis, which are critical for informed decisionmaking in Cell Line Development. Here, we propose a holistic method for digitizing the entire cell line development and selection process. Our approach begins with implementing laboratory and data automation tools to streamline the generation and handling of raw data. We then establish automated data pipelines using the Databricks platform, enabling the integration of various data types and data of different scales into a specially designed database. This database comprehensively encompasses data on cell line creation, assessment, and selection. Additionally, we develop visualization dashboards linked in real-time to the database, significantly reducing time spent on data processing. Finally, we leverage this streamlined data to build predictive models using open-source Python machine-learning algorithms, enhancing the cell line selection process. Our proposed digital framework ensures a data-driven approach, optimizing the selection of highquality cell lines for clinical and commercial manufacturing purposes.
- Yi Li - Process Development Scientist, Amgen, Inc.
- Mark Tie - Principal Scientist, Biogen
- Thomas Kelly - Director, Cell Engineering & Analytical Sciences, Johnson & Johnson Innovative Medicine
- Charles Mitchell - Senior Process Scientist, Cell Culture, Visterra Inc